• news.cision.com/
  • Nanoform/
  • Share subscriptions based on Nanoform Finland Plc's 2/2019 and 1/2020 Stock Option Programs
English

Share subscriptions based on Nanoform Finland Plc's 2/2019 and 1/2020 Stock Option Programs

Report this content

COMPANY RELEASE

September 2, 2020 at 03:00 p.m. Finnish time                             

Share subscriptions based on Nanoform Finland Plc's 2/2019 and 1/2020 Stock Option Programs

Between August 29 and August 31, 2020, a total of 16,671 Nanoform Finland Plc’s (the "Company" or "Nanoform") new shares have been subscribed for with the Company's 2/2019 and 1/2020 stock options. The entire subscription price for subscriptions made with the stock options of EUR 22,007.15 will be entered in the Company’s reserve for invested unrestricted equity.

The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about September 8, 2020 as of which date the new shares will establish shareholder rights. As a result of registering the new shares, the number of Nanoform shares is 66,600,443 in total. The new shares will be admitted to trading on Nasdaq First North Premier Growth Market Finland and Sweden on or about September 9, 2020.

For further information, please contact:

Peter Hänninen, General Counsel

peter.hanninen@nanoform.com / +358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform’s share is listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS)

For more information please visit http://www.nanoform.com

Subscribe

Documents & Links